Advances in Angiostatic Treatment for Retinal Disease: Demystifying Novel Therapeutic Targets (CME Webcast)
Activity Description and Purpose
Current challenges in the treatment of neovascular retinal disease include the tremendous burden of treatment and suboptimal response to treatment in many cases. Strides have been made recently toward therapies that deliver increased efficacy vs traditional first-line therapies, a decreased treatment burden, or both. To achieve these ends, next-generation treatment strategies target multiple angiogenic cellular pathways at once. In this activity, experts in retinal disease treatment use custom animations to discuss the mechanisms of action of various novel treatment strategies. The latest clinical trial data for faricimab and OPT-302, two molecules currently in phase 3 clinical trials for the treatment of retinal disease, are also presented.
This educational activity is intended for retina specialists and other ophthalmologists caring for patients with nAMD or DME.
After completing this activity, participants will be better able to:
- Describe pathophysiologic mechanisms of emerging combination approaches to treating neovascular age-related macular degeneration and diabetic macular edema
- Review the latest clinical trial data for approved and emerging combination treatments for neovascular age-related macular degeneration and diabetic macular edema
- Identify patients who would be good candidates for emerging combination treatment for their neovascular age-related macular degeneration or diabetic macular edema
|David A. Eichenbaum, MD|
Collaborative Associate Professor of Ophthalmology
Morsani College of Medicine
University of South Florida
Partner and Director of Research
Retina Vitreous Associates of Florida
|Charles C. Wykoff, MD, PhD|
Director of Research
Retina Consultants of Texas
Retina Consultants of America
Deputy Chair for Ophthalmology
Blanton Eye Institute
Houston Methodist Hospital
MedEdicus requires that anyone who is in a position to control the content of this educational activity disclose all relevant financial relationships with any commercial interest. Financial relationship information is collected and resolved prior to the educational activity.
David Eichenbaum, MD, is a consultant for Alimera Sciences, Allergan, Apellis Pharmaceuticals, D.O.R.C. Dutch Ophthalmic Research Center (International) B.V., EyePoint Pharmaceuticals, Genentech, Inc, Gyroscope, IVERIC bio, KKR, Kodiak Sciences Inc, Notal Vision, Novartis Pharmaceuticals Corporation, Recens Medical, Inc, and Regeneron Pharmaceuticals, Inc; is on the speakers bureau for Allergan, Bayer Corporation, D.O.R.C. Dutch Ophthalmic Research Center (International) B.V., EyePoint Pharmaceuticals, and Genentech, Inc; is a contracted researcher for Alkahest, Inc, Allergan, AsclepiX, Bayer Corporation, Chengdu Kanghong Pharmaceutical Group Co Ltd, Gemini Therapeutics, Genentech, Inc, Gyroscope, Ionis Pharmaceuticals, Inc, IVERIC bio, Kodiak Sciences Inc, Mylan NV, NGM Biopharmaceuticals, Novartis Pharmaceuticals Corporation, Opthea, and Regeneron Pharmaceuticals, Inc; and has ownership interest in Clearside Biomedical, Inc, and Hemera Biosciences.
Charles C. Wykoff, MD, PhD, is a consultant for Adverum, Allergan, Apellis Pharmaceuticals, Arctic Vision (Shanghai) Biotechnology Co., Ltd, Arrowhead Pharmaceuticals, Inc, Bausch & Lomb Incorporated, Bayer Corporation, Bionic Vision Technologies, Chengdu Kanghong Pharmaceutical Group Co Ltd, EyePoint Pharmaceuticals, F. Hoffmann-La Roche Ltd, Genentech, Inc, Gyroscope, IVERIC bio, Kato Pharmaceutical Inc, Kodiak Sciences Inc, Merck & Co., Inc, NGM Biopharmaceuticals, Novartis Pharmaceuticals Corporation, Occurx, Ocular Therapeutix, Inc, ONL Therapeutics, Opthea, Oxurion NV, Palatin Technologies, Inc, PolyPhotonix, Recens Medical, Inc, Regeneron Pharmaceuticals, Inc, Regenxbio Inc, Takeda Pharmaceuticals USA, Inc, Thea Pharmaceuticals Limited, and Verana Health; and is a contracted researcher for Adverum, Aerie Pharmaceuticals, Inc, Aldeyra Therapeutics, Alimera Sciences, Apellis Pharmaceuticals, Bayer Corporation, Boehringer Ingelheim, Chengdu Kanghong Pharmaceutical Group Co Ltd, Clearside Biomedical, Inc, F. Hoffmann-La Roche Ltd, Gemini Therapeutics, Genentech, Inc, GrayBug, Inc, Gyroscope, Ionis Pharmaceuticals, Inc, IVERIC bio, Kodiak Sciences Inc, Lowy Medical Research Institute, Neurotech Pharmaceuticals, NGM Biopharmaceuticals, Novartis Pharmaceuticals Corporation, Opthea, Outlook Therapeutics, Inc, Oxurion NV, Recens Medical, Inc, Regeneron Pharmaceuticals, Inc, Regenxbio Inc, Samchundang Pharm Co, Ltd, Santen Inc, Senju Pharmaceutical Co, Ltd, Taiwan Liposome Company, Ltd, and Xbrane Biopharma AB.
This activity was peer reviewed. The peer reviewer has no relevant financial relationships.
Planners and Managers
MedEdicus planners and managers have no relevant commercial relationships to disclose.
MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
MedEdicus LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Commercial Support
This continuing medical education activity is supported through an educational grant from Genentech, Inc.
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at firstname.lastname@example.org.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC, Genentech, Inc, or ReachMD.
This CME activity is copyrighted to MedEdicus LLC ©2021. All rights reserved. 246
- 0.50 AMA PRA Category 1 Credit™
- 0.50 Participation